Marijuana Moment: New Cannabis Group Will Help Ground Policy in Science and Patient Experience as Trump's Rescheduling Move Advances
The Marijuana Moment op-ed highlights a pivotal opportunity to shape federal cannabis policy as rescheduling efforts advance, with a new coalition aiming to ground decisions in scientific research and real patient outcomes. The article emphasizes growing evidence supporting medical cannabis—such as studies showing strong patient-reported benefits and improved quality of life—which reinforces the company’s focus on clinically informed cannabinoid therapies. From this standpoint, the initiative represents a chance to legitimize and standardize cannabis-based medicine at a federal level, positioning companies like Constance Therapeutics to contribute data, influence regulatory frameworks, and expand access to evidence-based treatments.
